- Home
- CUBI vs VERA Comparison
CUBI vs VERA Comparison
Compare CUBI & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CUBI
- VERA
- Stock Information
- Founded
- CUBI 1994
- VERA 2016
- Country
- CUBI United States
- VERA United States
- Employees
- CUBI N/A
- VERA N/A
- Industry
- CUBI Major Banks
- VERA Biotechnology: Pharmaceutical Preparations
- Sector
- CUBI Finance
- VERA Health Care
- Exchange
- CUBI Nasdaq
- VERA Nasdaq
- Market Cap
- CUBI 1.7B
- VERA 2.0B
- IPO Year
- CUBI 2012
- VERA 2021
- Fundamental
- Price
- CUBI $63.16
- VERA $23.20
- Analyst Decision
- CUBI Buy
- VERA Buy
- Analyst Count
- CUBI 9
- VERA 8
- Target Price
- CUBI $67.38
- VERA $64.63
- AVG Volume (30 Days)
- CUBI 381.4K
- VERA 1.3M
- Earning Date
- CUBI 07-24-2025
- VERA 08-07-2025
- Dividend Yield
- CUBI N/A
- VERA N/A
- EPS Growth
- CUBI N/A
- VERA N/A
- EPS
- CUBI 3.98
- VERA N/A
- Revenue
- CUBI $591,500,000.00
- VERA N/A
- Revenue This Year
- CUBI $12.60
- VERA N/A
- Revenue Next Year
- CUBI $10.57
- VERA N/A
- P/E Ratio
- CUBI $15.81
- VERA N/A
- Revenue Growth
- CUBI N/A
- VERA N/A
- 52 Week Low
- CUBI $40.75
- VERA $18.53
- 52 Week High
- CUBI $68.49
- VERA $51.61
- Technical
- Relative Strength Index (RSI)
- CUBI 69.39
- VERA 49.75
- Support Level
- CUBI $61.35
- VERA $22.57
- Resistance Level
- CUBI $67.04
- VERA $24.58
- Average True Range (ATR)
- CUBI 2.08
- VERA 1.13
- MACD
- CUBI 0.15
- VERA 0.06
- Stochastic Oscillator
- CUBI 68.38
- VERA 38.05
About CUBI Customers Bancorp Inc
Customers Bancorp Inc is a bank holding company engaged in banking activities. It provides financial products and services to small and middle-market businesses, not-for-profits, and consumers. The company operates in Lending Activities, Commercial Lending, Consumer Lending, Private Banking, Deposit Products, Other Funding Sources and Financial Products and Services. The majority of revenue is derived from commercial lending.
About VERA Vera Therapeutics Inc.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.